Vanderbilt University Medical Center (VUMC)

 

Videos
05:58

2024 ASH Annual Meeting Insights Hub

ASH 2024 Insights: Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone in RRMM

FEATURING Muhamed Baljevic
  • 2 views
  • December 16, 2024
17:01

Vanderbilt University Medical Center (VUMC)

Biomarkers for Immunotherapy in Melanoma: Where Are We Now?

FEATURING Douglas Johnson
  • 107 views
  • November 20, 2024
  • 2
15:27

Vanderbilt University Medical Center (VUMC)

Updates in CAR-T Therapy for Aggressive Lymphomas

FEATURING Bhagirathbhai Dholaria
  • 97 views
  • October 23, 2024
  • 1
12:17

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials

FEATURING Douglas Johnson
  • 195 views
  • September 25, 2024
04:04

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan vs. Everolimus in Patients With Previously Treated Advanced ccRCC

FEATURING Brian Rini
  • 99 views
  • September 25, 2024
13:57

Vanderbilt University Medical Center (VUMC)

Updates on Non-Invasive Screening for Colorectal Cancer

FEATURING Reid Ness
  • 206 views
  • September 9, 2024
10:37

Vanderbilt University Medical Center (VUMC)

Understanding Treatment Sequencing in Metastatic Melanoma: IO vs. Targeted Therapy

FEATURING Douglas Johnson
  • 226 views
  • August 5, 2024
  • 2
05:44

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "KEYNOTE-426 Trial - Biomarker Analysis of Pembro + Axitinib vs. Sunitinib for aRCC"

FEATURING Brian Rini
  • 105 views
  • June 17, 2024
11:42

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Atezolizumab & Varlilumab (CDX-1127) +/- Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer"

FEATURING Thatcher Heumann
  • 44 views
  • June 12, 2024
12:38

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Refining Treatment in Advanced Hepatobiliary Cancers"

FEATURING Laura Goff
  • 93 views
  • June 12, 2024
  • 1
11:05

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and Refractory Melanoma"

FEATURING Douglas Johnson
  • 518 views
  • June 7, 2024
  • 1
18:28

Vanderbilt University Medical Center (VUMC)

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Neoadjuvant & Later-Line Systemic Therapy

FEATURING Douglas Johnson
  • 407 views
  • April 25, 2024
  • 5
09:38

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Management of Non-ccRCC"

FEATURING Katy Beckermann
  • 85 views
  • February 8, 2024
22:07

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "How Old Is Too Old? Frailty & Geriatric Assessments of Older Adults Undergoing allo-HCT"

FEATURING Reena Jayani
  • 90 views
  • December 17, 2023
41:59

Fight Colorectal Cancer

Recent ASCO® CRC Updates Including PROSPECT, PRODIGE 23, OPRA, DESTINY-CRC02 & NeoCol Trials

FEATURING Cathy Eng
  • 206 views
  • August 25, 2023
  • 3
09:09

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Updated TRIMM-2 Results - Talquetamab + Daratumumab in Patients With R/R MM"

FEATURING Bhagirathbhai Dholaria
  • 154 views
  • July 16, 2023
  • 1
03:33

ecancer

ASCO® 2023 Insights: "TRIMM-2 Study Summary - Update on Talquetamab + Daratumumab for R/R MM"

FEATURING Bhagirathbhai Dholaria
  • 67 views
  • June 14, 2023
24:19

Vanderbilt University Medical Center (VUMC)

The Rapidly Growing Landscape of BCMA-Targeted Therapies

FEATURING Eden Biltibo
  • 191 views
  • June 9, 2023
  • 1
13:36

Vanderbilt University Medical Center (VUMC)

Venous Thromboembolism Prophylaxis in Newly Diagnosed MM

FEATURING Muhamed Baljevic
  • 440 views
  • June 7, 2023
  • 2
09:16

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase 1b/2 Study of Batiraxcept (AVB-S6-500) as Monotherapy, in Combination With Cabo, and in Combination With Cabo & Nivo in Patients With Advanced/Metastatic ccRCC"

FEATURING Katy Beckermann
  • 130 views
  • June 6, 2023
16:58

ESMO Breast Cancer 2023 Congress Coverage

ESMO Breast Cancer 2023: Who Really Benefits From IO? Can We Identify Subsets That Benefit and How to Measure?

FEATURING Justin Balko
  • 45 views
  • May 22, 2023
23:38

2023 West Oncology Conference

Improving the Quality of Life for Head & Neck Cancer Survivors: New Directions for Care

FEATURING Barbara Murphy
  • 1,015 views
  • March 15, 2023
  • 2
11:25

Total Health

Updates in the Management of Advanced HCC

FEATURING Thatcher Heumann
  • 159 views
  • March 8, 2023
12:39

Total Health

Updates in the Systemic Therapy for Biliary Tract Cancers

FEATURING Thatcher Heumann
  • 164 views
  • March 8, 2023
  • 1
08:23

Total Health

Updates in the SoC for 1L Pancreatic Adenocarcinoma

FEATURING Thatcher Heumann
  • 116 views
  • March 8, 2023
  • 1
35:58

Fight Colorectal Cancer

ASCO GI 2023 CRC Recap With Dr. Cathy Eng

FEATURING Cathy Eng
  • 138 views
  • March 7, 2023
  • 1
23:05

OncoAlert

The Year in Review for Colorectal and Anal Cancer

FEATURING Cathy Eng
  • 499 views
  • March 2, 2023
  • 4
26:13

Total Health

2023 Updates on Immunotherapy in Colorectal Cancer

FEATURING Kristen Keon Ciombor
  • 161 views
  • March 1, 2023
  • 3
49:24

Yale Cancer Center

Using and Improving the Real-World Data Ecosystem in Cancer

FEATURING Jeremy L. Warner
  • 42 views
  • January 23, 2023
  • 1
21:24

Penn Medicine Abramson Cancer Center

Anti-EGFR Antibody Imaging Strategies for Real-Time Surgical and Pathologic Guidance

FEATURING Eben Rosenthal
  • 64 views
  • January 5, 2023
  • 1
25:37

2022 MASCC/ISOO Annual Meeting on Supportive Care in Cancer

Mucositis: More Than Mouth Ulcers

FEATURING Barbara Murphy
  • 29 views
  • December 22, 2022
  • 1
11:42

SABCS 2022 Conference Coverage

SABCS 2022: Trastuzumab-Induced Tumor Microenvironment Changes in Early HER2+ BC

FEATURING Laura Kennedy
  • 86 views
  • December 16, 2022
12:08

Vanderbilt University Medical Center (VUMC)

ASCT in NDMM: Still Standard of Care?

FEATURING Muhamed Baljevic
  • 128 views
  • December 6, 2022
  • 1
21:13

Total Health

The Role of CAR T-Cell Therapy in DLBCL and B-ALL

FEATURING Bhagirathbhai Dholaria
  • 164 views
  • October 24, 2022
  • 1
18:47

Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

FEATURING Wade Iams
  • 6,426 views
  • October 20, 2022
  • 38
21:58

Total Health

ASCO 2022 Colorectal Updates: Phase III PARADIGM Trial, Phase II DYNAMIC Trial, Single Agent PD-1 Blockade in dMMR Locally Advanced Rectal Cancer

FEATURING Kristen Keon Ciombor
  • 257 views
  • August 31, 2022
05:47

ASCO 2022 Conference Coverage

ASCO 2022 Maturation of Overall Survival in TIVO-3 With Long-Term Follow-Up in R/R RCC

FEATURING Brian Rini
  • 644 views
  • June 8, 2022
  • 3
18:36

MDS Foundation

Difficult MDS Case: 75 y/o With Stable Disease on DNMTi After 6 Cycles, But Remains Pancytopenic and Transfusion-Dependent

FEATURING Michael Savona
  • 24 views
  • April 26, 2022
05:33

Catherine Watson

PARPi Maintenance Therapy in Advanced Ovarian Cancer: A Brief Review

  • 256 views
  • March 22, 2022
  • 2
17:21

2022 West Oncology Conference

Treatment Sequencing in R/R DLBCL in the Era of CAR-T

FEATURING Bhagirathbhai Dholaria
  • 27 views
  • March 15, 2022
17:36

2022 West Oncology Conference

The Evolving Role for IO in Upper GI Malignancies and Updates in Neuroendocrine Neoplasms

FEATURING Satya Das
  • 191 views
  • March 14, 2022
22:04

2022 West Oncology Conference

Current Status of Adjuvant and Frontline Therapies for Advanced RCC

FEATURING Brian Rini
  • 346 views
  • March 14, 2022
  • 2
11:32

ASCO Genitourinary Cancers Symposium

ASCO GU 2022: Phase II/III Clinical Results of IL-15RαFc Superagonist N-803 With BCG in BCG-Unresponsive NMIBC

FEATURING Sam Chang
  • 27 views
  • March 8, 2022
40:21

Nebraska Oncology Society

2022 Nebraska Oncology Society SABCS Review: Neo(Adjuvant) Breast Cancer Therapy Highlights

FEATURING Laura Kennedy
  • 229 views
  • March 2, 2022
  • 1
10:54

Vanderbilt University Medical Center (VUMC)

External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy

FEATURING Satya Das
  • 142 views
  • February 9, 2022
  • 1
25:57

2021 Virtual ESMO Review

ESMO 2021 Highlights on Advanced Colorectal Cancers: AtezoTRIBE, EPOCH, DESTINY CRC-01, and MAYA Trials

FEATURING Cathy Eng
  • 210 views
  • November 8, 2021
  • 1
21:46

Total Health

Updates on Soft Tissue Sarcoma: Complexities of Pathological Diagnosis, AJCC Staging System, and Systemic Therapy Options for Localized & Metastatic Disease

FEATURING Elizabeth Davis
  • 237 views
  • October 20, 2021
  • 4
18:55

Total Health

Systemic Therapy Updates in Advanced RCC: IO+VEGF, IO+IO, and HIF Inhibition

FEATURING Brian Rini
  • 151 views
  • October 13, 2021
  • 1
14:17

Extracellular Vesicles and Their Role in Patients With Multiple Myeloma

Overview of Tools for Tracking Biodistribution of Cancer EVs

FEATURING Bong Hwan Sung
  • 2 views
  • August 3, 2021
10:37

Vanderbilt University Medical Center (VUMC)

ASCO 2021 Update on Platinum-Based Chemo vs. Capecitabine in Residual TNBC Following Neoadjuvant Chemo: ECOG-ACRIN EA1131 Data

FEATURING Ingrid Mayer
  • 459 views
  • June 16, 2021
17:48

Bladder Cancer Symposium: Update on Medical and Surgical Management for the Urologist

2021 Updates on Treatment, Surveillance, and Guidelines for NMIBC: How to Perform Quality TURBT? What Options Do We Have When No BCG Is Available? Is Active Surveillance Effective for Low-Risk Patients?

FEATURING Sam Chang
  • 13 views
  • May 5, 2021
15:01

Virtual West Oncology Conference

2021 Updates on NMIBC: Low-Grade vs. High-Grade pTa, pT1, Carcinoma in Situ, Intravesical Chemo (Mitomycin C, Gemcitabine), BCG, Refractory High-Grade Disease

FEATURING Amy Luckenbaugh
  • 53 views
  • March 5, 2021
21:41

University of Kansas Cancer Center Post San Antonio Review

Endocrine Resistance in BC: Mechanisms and Treatment Strategies

FEATURING Justin Balko
  • 143 views
  • February 28, 2021
31:02

University of Kansas Cancer Center Post San Antonio Review

Genomic Signatures in Adjuvant Therapy of HR+ EBC: Should We Consider Abemaciclib x2 Years to ET in Very-High Risk Patients? Can Longer CDK4/6i Duration Prevent Late Relapses?

FEATURING Ingrid Mayer
  • 212 views
  • February 28, 2021
  • 1
35:25

Virtual Diversity in Cancer Care

Cancer Disparities in the US: Historical Perspectives on Race and Current Challenges - What Can You Do to Close the Gaps?

FEATURING Kelvin Moses
  • 9 views
  • February 13, 2021
13:16

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Cardio-Oncology Update: What Is the Long Term Efficacy of DRZ as a Cardioprotectant Among Childhood Cancer Survivors? Is There a Negative Impact of DRZ on Cancer Outcomes?

FEATURING Daniel Lenihan
  • 10 views
  • February 12, 2021
19:13

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Cardio-Oncology: How Does It Impact Treatment Choices and Outcomes? What Are the Prosper Study Results?

FEATURING Daniel Lenihan
  • 9 views
  • February 12, 2021
22:42

2nd Annual International Gastric Cancer Educational Symposium

Understanding Clinical Trials in Oncology: How Do Risk/Benefits Compare to Standard Treatment? What Is the Difference Between Clinical Trial vs. Study vs. Protocol?

FEATURING Jordan Berlin
  • 10 views
  • January 11, 2021
06:49

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Updates on Locally Advanced Oropharynx Cancer: Can Surgery Enable Equivalent Efficacy With a Lower Dose of Adjuvant Radiation?

FEATURING Michael Gibson
  • 11 views
  • September 29, 2020
06:02

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on HNSCC: Weekly vs. 3-Weekly Cisplatin - What Is the Appropriate/Cumulative Dose?

FEATURING Michael Gibson
  • 19 views
  • September 29, 2020
08:48

2020 ASCO Virtual Direct™ Highlights

2020 ASCO Highlights on Recurred/Metastatic ACC: Does Axitinib Increase PFS Rate Compared to Observation? How Does Tipifarnib Affect H&N Tumors With HRAS Mutations?

FEATURING Michael Gibson
  • 14 views
  • September 29, 2020
13:55

Rush University Medical Center's Changing the Game in Lung Cancer Treatment: Precision Medicine in 2020

Rush 2020 Update on ALK+ NSCLC: What Is the Preferred 1L ALK TKI? What Are the Options to Overcome 1L Alectinib Resistance?

FEATURING Christine Lovly
  • 297 views
  • September 25, 2020
  • 3
19:03

Rush University Medical Center's Changing the Game in Lung Cancer Treatment: Precision Medicine in 2020

Rush 2020 Update on EGFR+ NSCLC: How Should You Treat Resistance to 1L Osimertinib? What Is the Preferred 1L EGFR TKI?

FEATURING Christine Lovly
  • 287 views
  • September 25, 2020
  • 2
15:54

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Role of DNA Methyltransferase Inhibitors in the Modern Therapy of MDS

FEATURING Michael Savona
  • 11 views
  • November 19, 2019